H2020-JTI-IMI2-2015-05-two-stage

Update! The European Medicines Agency (EMA) is willing to join the selected applicant consortium for the full proposal submission (stage two) of the topic 'Patient perspective elicitation on benefits and risks of medicinal products, from development through the entire life cycle, to inform the decision-making process by regulators and health technology assessment bodies' together with the industry consortium. The proposed EMA contribution can be found here (and on the IMI web site) for consideration by the applicant consortia. The EMA will cover its own participation costs. For more information please contact the IMI Infodesk (infodesk@imi.europa.eu) and/or the EMA (henry.fitt@ema.europa.eu).